Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.48 |
| ▸ | METAP1 | P53582 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.46 |
| ▸ | MTOR | P42345 | 5/20 | 0.46 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.46 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.46 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14902608 | 0.88 | MAPK1 (0.47) | SYKMETAP1ALOX15MAPK1PIK3CA | |
| SCHEMBL2588826 | 0.85 | PIK3CD (0.57) | SYKMETAP1ALOX15MAPK1PIK3CA | |
| SCHEMBL2580739 | 0.85 | ALOX15 (0.47) | SYKMETAP1ALOX15MAPK1PIK3CA | |
| SCHEMBL14900561 | 0.81 | SYK (0.53) | SYKMETAP1ALOX15MAPK1PIK3CA | |
| SCHEMBL2589305 | 0.81 | PIK3CA (0.48) | SYKMETAP1ALOX15MAPK1PIK3CA | |
| SCHEMBL2589911 | 0.80 | SYK (0.47) | SYKMETAP1ALOX15MAPK1PIK3CA | |
| SCHEMBL2588987 | 0.80 | METAP1 (0.47) | SYKMETAP1ALOX15MAPK1PIK3CA | |
| SCHEMBL1858428 | 0.77 | SYK (0.56) | SYKMETAP1ALOX15MAPK1MTOR | |
| SCHEMBL14902650 | 0.77 | ALOX15 (0.47) | SYKMETAP1ALOX15MAPK1PIK3CA | |
| SCHEMBL14902606 | 0.76 | ALOX15 (0.47) | SYKMETAP1ALOX15MAPK1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266879-B2 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTIC LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-9266879-B2 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTIC LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-9266879-B2 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTIC LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| EP-2563788-B1 | NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE-INFLAMMATORY DISEASES | KARUS THERAPEUTICS LTD (GB) | 2015-08-05 | — | — | EP | disclosed |
| EP-2563788-B1 | NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE-INFLAMMATORY DISEASES | KARUS THERAPEUTICS LTD (GB) | 2015-08-05 | — | — | EP | disclosed |
| US-20130109688-A1 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTICS LIMITED (UK) | 2013-05-02 | — | — | US | disclosed |
| US-20130109688-A1 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTICS LIMITED (UK) | 2013-05-02 | — | — | US | disclosed |
| US-20130109688-A1 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTICS LIMITED (UK) | 2013-05-02 | — | — | US | disclosed |
| EP-2563788-A1 | NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE - INFLAMMATORY DISEASES | Karus Therapeutics Limited (GB) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011135351-A1 | NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE - INFLAMMATORY DISEASES | KARUS THERAPEUTICS LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011135351-A1 | NAPHTHRIDINE DERIVATIVES AS PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNE - INFLAMMATORY DISEASES | KARUS THERAPEUTICS LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109688-A1 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | PIK3R5, PIK3CA, NFKBIA | SYK 140/4885METAP1 4495/4885ALOX15 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.